The Project Management of Project Management - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Project Management of Project Management
This article presents an overview of ISPE's guide on project management.


Pharmaceutical Technology
Volume 36, Issue 9, pp. s26-s29

Defining the scope

Once the full delivery strategy had been developed and approved, the guide team focused on the introduction chapter detailing the guide purpose, benefits, industry context, and scope.


Figure 3: The scope of the guide.
The scope was the hardest part of this work. There are many project types as a pharmaceutical product moves from an idea to a manufactured drug for sale in the market. A boundary had to be drawn (see Figure 3), thus giving the chapter teams clear guidance that linked to their subject-matter expertise.


Figure 4: The guide’s key concepts.
The discussions on scope led into agreement on which project types would be supported by the guide and also the fundamental concepts to direct SME chapter writers on what content should be included or not included in each chapter (see Figure 4). The eight key concepts were a checklist of content relevance, approach, and value to pharma products.

Project delivery


Figure 5: The key structure of the guide.
Once Chapter One was written, the delivery of the lifecycle chapters began (Figure 5). In any project, the management of uncertainty becomes the key focus, and the guide project was no different. The guide was managed using a risk-based approach; all areas of uncertainty were identified and managed. A good example is the way that chapter content and schedule adherence were reviewed.


Figure 6: The risk matrix. (FIGURE 6 COURTESY OF MIME)
Each chapter team was clear on the definition of project success: "develop a valuable industry guide and launch it at the 2011 ISPE Annual Meeting in record time (18 months from start to finish)." Schedule and technical-content risks were analyzed using the Risk Matrix (see Figure 6). Risks were assessed for probability of occurrence and impact on the chapter goals should they occur. Each chapter was given a red, amber, green (RAG) rating dependent on these two factors, thereby enabling the core steering team to predict likely success. Control of the project schedule and risk profile were managed through regular virtual meetings, allowing a one-team approach no matter where in the world a team member was located.

The guide team attributed a significant part of its success in having true "working sessions" via a webex platform. Action logs were generated "live" with no need to write lengthy minutes after the fact. Chapters were written and reviewed "live," thereby avoiding the need for team members to have extended writing sessions outside of the virtual environment. Work was available on a shared e-area, which avoided revision conflicts and emailing large documents. Through lean working, the team was able to write high quality chapters in agile time-scales to allow the guide to go out for a full industry review only eight months after the project was launched.

Writing the guide, however, was only one stage in its lifecycle. The review process involved a wider group of stakeholders whose role was to evaluate the guide in terms of technical accuracy, appropriateness, and value to the industry. This review was managed in a structured way to ensure that all comments were responded to by the team.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
25%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here